Microvesicles (mvs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease

Abstract

The invention is in the field of therapeutic treatment of tumours. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumour effect when administered to a patient affected by a tumour disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.

1 - 20 . (canceled) 
     
     
         21 . A method for treating a tumor disease comprising administering to a patient in need thereof
 a therapeutically effective amount of microvesicles (MVs) derived from an adult stem cell and   a therapeutically effective amount of at least, one of one or more cytotoxic agents and one or more cytostatic agents.   
     
     
         22 . The method according to  claim 21 , wherein the cytotoxic and cytostatic agents are selected from the group consisting of Paclitaxel, Lenalidomide, Pomalidomide, Eprirubicin, 5FU, Sunitinib, La-patinib, Canertinib, cyclophosphamide, doxorubicin, Lenalidomide/Dexamethasone, Pomalidomide/Dexamethasone, Carboplatin, Rapamycin, mitoxantron, oxaliplatin, docetaxel, vinorelbin, vincristine, and combinations thereof. 
     
     
         23 . The method according to  claim 21 , wherein the cytotoxic and cytostatic agents are doxorubicin or vincristine. 
     
     
         24 . The method according to  claim 21 , wherein the adult stem cell is a mesenchymal stem cell. 
     
     
         25 . The method according to  claim 21 , wherein the adult stem cell is a human mesenchymal stem cell derived from bone marrow (BM-MSC) or a human mesenchymal stem cell derived from decapsulated glomeruli (GI-MSC). 
     
     
         26 . The method according to  claim 21 , wherein the adult stem cell is a liver stem cell. 
     
     
         27 . The method according to  claim 21 , wherein the adult stem cell is a non-oval liver stem cell (HLSC). 
     
     
         28 . The method according to  claim 21 , wherein the tumour disease is selected from the group consisting of liver tumour, epithelial tumour, breast tumour, lung tumour, prostate tumour, gastric tumour, colon tumour, and ovarian tumour. 
     
     
         29 . The method according to  claim 21 , comprising administering the microvesicles in a dose of 0.1 to 200 micrograms/kg body weight of the patient. 
     
     
         30 . The method according to  claim 21 , comprising administering the microvesicles in a dose of 1-150 micrograms/kg body weight of the patient. 
     
     
         31 . The method according to  claim 21 , comprising administering the microvesicles in a dose of 3-120 micrograms/kg body weight in the patient. 
     
     
         32 . The method according to  claim 21 , wherein the microvesicles are administered through a local or a systemic route.